Research programme: anti-fungals - ElitraAlternative Names: Anti-fungals research programme - Elitra
Latest Information Update: 19 Apr 2007
At a glance
- Originator Concordia University; Elitra Canada (CEASED); McGill University; Natural Sciences and Engineering Research Council of Canada; University of Toronto
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 19 Apr 2007 Discontinued - Preclinical for Mycoses in Canada (unspecified route)
- 02 Jul 2002 This programme is still in active development
- 22 Dec 2000 Mycota Biosciences has been acquired by Elitra Pharmaceuticals and renamed Elitra Canada